Acid Treatment of FVIII-Containing Plasma Samples Unmasks a Broad Spectrum of FVIII-Specific Antibodies in ELISA

Abstract

During routine treatment, plasma samples of patients with hemophilia A or acquired hemophilia A are frequently analyzed for the presence of FVIII-specific antibodies. While only inhibitory antibodies can be detected by the Bethesda assay, inhibitory and non-inhibitory antibodies can be detected by ELISA. However, plasma samples of patients frequently contain endogenous or substituted FVIII, hence interfering with both types of analyses. One option for the inactivation of FVIII is heat denaturation, which unfortunately has been shown to lead to high background signals complicating the discrimination of negative and positive plasma samples. In the current study, we developed a method of acid denaturation for FVIII-containing plasma samples that can help identify samples containing FVIII-specific antibodies and compared the effects of heat and acid denaturation on the detection of FVIII–antibody interactions in a monoclonal setting. The aim of our study was to establish an analysis that allows safer treatment decisions in the context of tolerance to FVIII.

Keywords

hemophilia A/B - factor VIII inhibitors - inherited coagulation disorders

Publikationsverlauf

Eingereicht: 12. Februar 2024

Angenommen: 15. Mai 2024

Artikel online veröffentlicht:
15. Juli 2024

• References

• 1 Hoyer LW. Hemophilia A. N Engl J Med 1994; 330 (01) 38-47
• 2 Iorio A, Halimeh S, Holzhauer S. et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost 2010; 8 (06) 1256-1265
• 3 Batty P, Hart DP, Platton S. Optimization of pre-analytical heat treatment for inhibitor detection in haemophilia A. Int J Lab Hematol 2018; 40 (05) 561-568
• 4 Batty P, Platton S, Bowles L, Pasi KJ, Hart DP. Pre-analytical heat treatment and a FVIII ELISA improve factor VIII antibody detection in acquired haemophilia A. Br J Haematol 2014; 166 (06) 953-956
• 5 Boylan B, Miller CH. Effects of pre-analytical heat treatment in factor VIII (FVIII) inhibitor assays on FVIII antibody levels. Haemophilia 2018; 24 (03) 487-491
• 6 Hasselaar P, Triplett DA, LaRue A. et al. Heat treatment of serum and plasma induces false positive results in the antiphospholipid antibody ELISA. J Rheumatol 1990; 17 (02) 186-191
• 7 Jungkind DL, DiRenzo SA, Young SJ. Effect of using heat-inactivated serum with the Abbott human T-cell lymphotropic virus type III antibody test. J Clin Microbiol 1986; 23 (02) 381-382
• 8 Müller J, Neimanis S, Kahle J. et al; ABIRISK Consortium. Two-center validation of assays for the detection of binding and neutralizing anti-factor VIII antibodies. Haemophilia 2024; 30 (01) 224-231
• 9 Hofbauer CJ, Whelan SFJ, Hirschler M. et al. Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans. Blood 2015; 125 (07) 1180-1188
• 10 Schweiger H, Rejtő J, Hofbauer CJ. et al. Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors. Blood Adv 2022; 6 (03) 946-958
• 11 Kasper CK, Aledort L, Aronson D. et al. Proceedings: a more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34 (02) 612
• 12 Patton A, Mullenix MC, Swanson SJ, Koren E. An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. J Immunol Methods 2005; 304 (1-2): 189-195
• 13 Vermeer AW, Norde W. The thermal stability of immunoglobulin: unfolding and aggregation of a multi-domain protein. Biophys J 2000; 78 (01) 394-404